Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis

被引:435
作者
Durham, SR
Yang, WH
Pedersen, MR
Johansen, N
Rak, S
机构
[1] Royal Brompton & Harefield Hosp NHS Trust & Imper, Natl Heart & Lung Inst, London SW3 6LY, England
[2] Allergy & Asthma Res Ctr, Ottawa, ON, Canada
[3] ALK Abello AS, Horsholm, Denmark
[4] Sahlgrens Univ Hosp, Sect Allergy, Gothenburg, Sweden
基金
英国医学研究理事会;
关键词
specific immunotherapy; sublingual immunotherapy; grass allergen tablets;
D O I
10.1016/j.jaci.2005.12.1358
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Specific immunotherapy is the only treatment modality that has the potential to alter the natural course of allergic diseases. Sublingual immunotherapy has been developed to facilitate access to this form of treatment and to minimize serious adverse events. Objective: To investigate the efficacy and safety of sublingual grass allergen tablets in seasonal allergic rhinoconjunctivitis. Methods: A multinational, multicenter, randomized, placebo-controlled trial conducted during 2002 and 2003. Fifty-five centers in 8 countries included 855 participants age 18 to 65 years who gave a history of grass pollen-induced allergic rhinoconjunctivitis and had a positive skin prick test and elevated serum allergen-specific IgE to Phleum pratense. Participants were randomized to 2500, 25,000, or 75,000 SQ-T grass allergen tablets (GRAZAX; ALK-Abello, Horsholm, Denmark) or placebo for sublingual administration once daily. Mean duration of treatment was 18 weeks. Results: Average rhinoconjunctivitis scores during the season showed moderate reductions of symptoms (16%) and medication use (28%) for the grass allergen tablet 75,000 SQ-T (P =.0710; P =.0470) compared with placebo. Significantly better rhinoconjunctivitis quality of life scores (P =.006) and an increased number of well days (P =.041) were also observed. Efficacy was increased in the subgroup of patients who completed the recommended preseasonal treatment of at least 8 weeks before the grass pollen season (symptoms, 21%, P =.0020; and medication use, 29%, P =.0120). No safety concerns were observed. Conclusion: This study confirms dose-dependent efficacy of the grass allergen tablet. Although further studies are required, the greater tolerability of the tablet may permit immunotherapy to be available to a much broader group of patients with impaired quality of life caused by grass pollen allergy. Clinical implications: For patients with grass pollen allergy, sublingual immunotherapy is well tolerated and can reduce symptoms and improve quality of life.
引用
收藏
页码:802 / 809
页数:8
相关论文
共 27 条
[11]  
Feliziani V, 1993, Allergol Immunopathol (Madr), V21, P173
[12]   Immunotherapy with partially purified and standardized tree pollen extracts .4. Results from long-term (6-year) follow-up [J].
Jacobsen, L ;
Petersen, BN ;
Wihl, JA ;
Lowenstein, H ;
Ipsen, H .
ALLERGY, 1997, 52 (09) :914-920
[13]   Preventive aspects of immunotherapy: prevention for children at risk of developing asthma [J].
Jacobsen, L .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2001, 87 (01) :43-46
[14]   DEVELOPMENT AND TESTING OF A NEW MEASURE OF HEALTH-STATUS FOR CLINICAL-TRIALS IN RHINOCONJUNCTIVITIS [J].
JUNIPER, EF ;
GUYATT, GH .
CLINICAL AND EXPERIMENTAL ALLERGY, 1991, 21 (01) :77-83
[15]   COMPLEMENTARY-DNA CLONING OF THE MAJOR ALLERGEN PHL-P-I FROM TIMOTHY GRASS (PHLEUM-PRATENSE) - RECOMBINANT PHL-P-I INHIBITS IGE BINDING TO GROUP-I ALLERGENS FROM 8 DIFFERENT GRASS SPECIES [J].
LAFFER, S ;
VALENTA, R ;
VRTALA, S ;
SUSANI, M ;
VANREE, R ;
KRAFT, D ;
SCHEINER, O ;
DUCHENE, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (04) :689-698
[16]   Manufacturing and standardizing allergen vaccines [J].
Larsen, JN ;
Lowenstein, H .
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2000, 20 (03) :609-+
[17]  
LARSEN JN, 1999, ALLERGENS ALLERGEN I, P297
[18]   Is sublingual immunotherapy clinically effective? [J].
Malling, Hans-Jorgen .
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 2 (06) :523-531
[19]   Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study) [J].
Möller, C ;
Dreborg, S ;
Ferdousi, HA ;
Halken, S ;
Host, A ;
Jacobsen, L ;
Koivikko, A ;
Koller, DY ;
Niggemann, B ;
Norberg, LA ;
Urbanek, R ;
Valovirta, E ;
Wahn, U .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (02) :251-256
[20]   DOES THE EFFECT OF IMMUNOTHERAPY LAST AFTER TERMINATION OF TREATMENT - FOLLOW-UP-STUDY IN PATIENTS WITH GRASS-POLLEN RHINITIS [J].
MOSBECH, H ;
OSTERBALLE, O .
ALLERGY, 1988, 43 (07) :523-529